Lacha 2001.

Methods	open label RCT
Participants	Setting: Single centre Country: Czech Republic Immunologically high risk kidney transplant recipients (PRA > 50% or previous graft loss due to rejection during first year) Age: NS Number (group 1/group 2): 72 (38/34) Exclusions: NS
Interventions	Treatment group 1 Daclizumab: 2 mg/kg then 1 mg/kg on day 7, 14 and 28 Treatment group 2 Muromonab‐CD3: 5 mg day 1 then 2.5 mg days 2‐7 Baseline immunosuppression CSA: 8 mg/kg then tapered according to trough levels (NS) MMF: 2 g/d Steroids: NS
Outcomes	Graft loss Acute rejection CMV Adverse reaction
Notes	6 month follow‐up New data available form 2004 abstract (more participants)
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Stated "randomised" no further information provided
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding (performance bias and detection bias) Objective outcomes	Unclear risk	Open‐label, blinding of outcome assessors not stated
Blinding (performance bias and detection bias) Subjective outcomes	Unclear risk	Open‐label, blinding of outcome assessors not stated
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Unclear reporting of numbers in each group
Selective reporting (reporting bias)	Unclear risk	Death not reported, discussion states "...graft outcomes, survival rates and graft function is similar in both groups"
Other bias	Unclear risk	Source of funding not stated